BCYC241220C15000
- 5.50
- -0.20-3.51%
Bicycle Therapeutics Newsroom
European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading
Needham Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $38
Positive Outlook on Bicycle Therapeutics Driven by Promising Data and Upcoming Updates
Bicycle Therapeutics Plans To Present Data At SABCS; Abstract Outlines Data Showing Enhanced Anti-Tumor Activity Of Zelenectide Pevedotin Monotherapy In Triple-negative Breast Cancer Patients With NECTIN4 Gene Amplification
Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
Stephens Initiates Bicycle Therapeutics(BCYC.US) With Hold Rating, Announces Target Price $25
Stephens Sees 'Uphill Battle' for Bicycle Therapeutics, Starts at Equal Weight
Morgan Stanley Initiates Bicycle Therapeutics(BCYC.US) With Hold Rating, Announces Target Price $30
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
Bicycle Therapeutics Plc (NASDAQ:BCYC) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
JMP Securities Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $32
Barclays Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $55
RBC Capital Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $35
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | RBC Capital Reiterates Outperform on Bicycle Therapeutics, Maintains $35 Price Target
Bicycle Therapeutics Analyst Ratings
Bicycle Therapeutics GAAP EPS of -$0.74 Beats by $0.02, Revenue of $2.68M Misses by $4.33M
Bicycle Therapeutics | 10-Q: Q3 2024 Earnings Report